# Alafi Capital

> Alafi Capital is a VC fund backing Biotechnology and Health Care. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 13
- Last investment: Nov 2023
- Lead investor: 15%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/alafi-capital-corp/about/
- Website: http://www.alafi.com

Alafi Capital is a private venture capital firm specialized in early- and mid-stage investments in the U.S. and Europe healthcare industry.

## Contacts

5 contacts available for Alafi Capital. Shizune tracks 4 team members at Alafi Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alafi-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 69% |
| Health Care | 5 | 38% |
| Medical Device | 3 | 23% |
| Health Diagnostics | 3 | 23% |
| Medical | 2 | 15% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 9 | 69% |
| Funding Round | 2 | 15% |
| Series A | 1 | 8% |
| Series E | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 54% |
| The Netherlands | 2 | 15% |
| France | 1 | 8% |
| Sweden | 1 | 8% |
| Germany | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chris Alafi | General partner | 1 | https://shizune.co/investors/profile/chris-alafi |
| Bill Weiss | CFO | 0 | https://shizune.co/investors/profile/bill-weiss |
| Karen Del Arroz | Office Manager | 0 | https://shizune.co/investors/profile/karen-del-arroz |
| Moshe Alafi | General partner | 0 | https://shizune.co/investors/profile/moshe-alafi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Incision | Incision is a developer of a medical education platform built to offer a standardized method of how to perform a procedure in practical steps and sub-steps. | $7M | Series B | Nov 01, 2023 |  |
| Resolve BioSciences | Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights in spatial biology. | $71M | Series B | Oct 24, 2022 |  |
| Edifice Health | Edifice Health is a spin-out company from a 10-year research study on immune profiling from Stanford University, the Stanford 1,000 Immunomes Project. The technology is the first biomarker composite scoring system to measure immune health and the Inflammatory Age® of an individual which predicts the onset of multiple chronic diseases and providescomprehensive health insights designed to help people change the course of their aging process. | $12M | Series A | Apr 22, 2021 |  |
| Bolt | Bolt is a materials company that invents and scales materials that put the planet on a path towards a better future. Biofabricated silk fibers MicrosilkTM - based on proteins found in nature, produced using Bolt Threads proprietary technology and revolutionary bioengineering concepts. Next-generation of performance fibers, fabrics and luxuryproducts that represent cutting-edge technology in science, while raising the bar for quality, performance, and design. | $32.3M | Series B | Jun 04, 2015 |  |
| Kreatech Diagnostics | Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry. | $2.7M | Series B | Jan 31, 2010 |  |
| Arcxis Biotechnologies | Arcxis Biotechnologies is focused on developing elegant, integrated and compact solutions to molecular diagnostic challenges. From proprietary microfluidics to advanced detection methods; streamlined sample preparation to comprehensive automation technology, we are in the business of making molecular methods more reliable, robust and accessible. |  | Series B | Feb 02, 2009 |  |
| Natera | Natera specializes in cell-free DNA testing is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. | $6M | Series B | Jan 19, 2009 |  |
| Isto Technologies | ISTO Technologies, Inc., an orthobiologics company, develops biologic products to regenerate and restore function to damaged cartilage and bone. It offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regenerationof knee cartilage. The company provides its products through distributors. ISTO Technologies, Inc. was founded in 1997 and is based in St. Louis, Missouri. | $8.8M | Series E | Aug 03, 2007 |  |
| Stereotaxis | Stereotaxis focuses on the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physiciansaround the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables. | $20M |  | Jan 10, 2003 |  |
| Direct Conversion | Direct Conversion provides detectors into imaging systems that are used across the globe | $23.3M |  | Jul 01, 2002 |  |

10 of 13 investments shown.

## Co-investors
- [HealthCap](https://shizune.co/investors/profile/healthcap) — VC Fund, 3 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 2 deals together
- [Claremont Creek Ventures](https://shizune.co/investors/profile/claremont-creek-ventures) — VC Fund, 2 deals together
- [Concordia](https://shizune.co/investors/profile/concordia-7fb2) — VC Fund, 2 deals together
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Alafi Capital invest in?

Alafi Capital invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series B and Funding Round stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Alafi Capital?

Public channels for Alafi Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alafi Capital?

The team at Alafi Capital includes Chris Alafi (General partner), Bill Weiss (CFO) and Karen Del Arroz (Office Manager). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co